



A CSR Initiative



# JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3<sup>rd</sup> Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)

November 19, 2024

The Department of Corporate Services- Listing <b>BSE Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 <b>Scrip Code: 507789</b>	The Department of Corporate Services- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 <b>Symbol: JAGSNPHARM</b>
---	--

**Sub: Update on Intimation as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Sale of Company’s Faridabad facility**

We refer to our intimation dated November 03, 2023 and July 25, 2024 wherein we had informed that the Company had entered into an Agreement to Sale to divest the Faridabad Facility.

We now wish to inform you that the company has received full consideration of Rs. 41 Crores towards the sale of facility and will now be proceeding with registration formalities.

We request you to take the same on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

**Abhishek Joshi**

**Company Secretary & Compliance Officer**